MBX Biosciences, a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, announced a $63.5 million Series C financing led by Deep Track Capital, with participation from new investors Driehaus Capital Management and funds and accounts advised by T. Rowe Price Associates, Inc. as well as existing investors Frazier Life Sciences, OrbiMed and Wellington Management, complementing our existing investor base, including New Enterprise Associates (NEA), Norwest Venture Partners and RA Capital Management.